$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How long does it take on average for platinib (Pujihua) to develop resistance and countermeasures
2026-02-01 22:25:32
Check Details
Analysis of the differences in pharmacological effects of capmatinib (Touradida) and cabozantinib
2026-02-01 22:25:32
Check Details
Analysis on the price and purchase channel safety of Indian version of Sotorashib (AMG 510)
2026-02-01 22:25:32
Check Details
Approved indications of adagrasib (Krazati) and possible future therapeutic areas expansion
2026-02-01 22:25:32
Check Details
Analysis of prices and market differences of different versions of Larotrectinib
2026-02-01 22:25:32
Check Details
How Selinisol (Silvio) treats non-Hodgkin lymphoma and its efficacy evaluation
2026-02-01 22:25:32
Check Details
Analysis of the mechanism of action of Vigabatrin (Okeda) and its targets in the nervous system
2026-02-01 22:25:32
Check Details
Mobosetinib (Anvili) is developed by which company and its production background is introduced
2026-02-01 22:25:32
Check Details
Is Tepotinib (Tuodekang) a targeted drug and analysis of its mechanism of action
2026-02-01 22:25:32
Check Details
Regorafenib (Belvango) complete instructions and what you need to know before taking it
2026-02-01 22:25:32
Check Details
Analysis of whether pazopanib (Viant) is a targeted drug and its action characteristics
2026-02-01 22:25:32
Check Details
Opicapone usage and dosage and adjustment plans for different patients
2026-02-01 22:25:32
Check Details
1
2
...
1991
1992
1993
1994
1995
1996
1997
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
2
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
3
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
4
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
5
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
6
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
7
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
8
Revumenib: Key Considerations Before and During Treatment
9
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
10
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
11
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
12
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use